Recurrent Salivary Gland Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0037143 (Recurrent Salivary Gland Carcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02538510Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryTreatment